Clinical Trials Logo

Heart Failure, Diastolic clinical trials

View clinical trials related to Heart Failure, Diastolic.

Filter by:

NCT ID: NCT01163734 Completed - Clinical trials for Diastolic Heart Failure

Ranolazine in Diastolic Heart Failure

RALI-DHF
Start date: April 2010
Phase: Phase 2
Study type: Interventional

Patients with CAD and clinical symptoms of heart failure or patients with suspected heart failure with preserved ejection fraction (HFpEF) will be enrolled. Study drug will be given as continuous IV infusion followed by oral treatment for 13 days. LV pressures and hemodynamic data will be measured prior to and after administration of study drug. In addition, Doppler ECHO, cardiopulmonary exercise testing (CPET), and NT-pro-BNP determination will be performed. Adverse events and safety labs will be collected and monitored.

NCT ID: NCT01157481 Active, not recruiting - Clinical trials for Diastolic Heart Failure

Diastolic Heart Failure Management by Nifedipine

DEMAND
Start date: July 2010
Phase: N/A
Study type: Interventional

Patients with heart failure with preserved ejection fraction have a equally high risk for mortality and re-hospitalization as those with reduced ejection fraction. Effective management strategies are critically needed to be established for this type of heart failure. These patients have more hypertensive and ischemic etiology than those with reduced ejection fraction. The investigators hypothesis is that Ca channel blocker nifedipine can improve the heart failure clinical composite response endpoint compared with the conventional treatment in patients with heart failure with hypertension and/or coronary artery disease and preserved ejection fraction (>=50%) by echocardiography. This study is multi-center, prospective, randomized, open-label, and blinded-endpoint design.

NCT ID: NCT01156636 Completed - Clinical trials for Pulmonary Hypertension

Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure

Start date: January 2006
Phase: Phase 2/Phase 3
Study type: Interventional

Prevalence of heart failure (HF) with left ventricular (LV) diastolic dysfunction and preserved ejection fraction (EF) (HFpEF) is increasing. Prognosis worsens with development of pulmonary vasoconstriction and hypertension (PH) and right ventricular (RV) failure. The investigators aimed at modulating pulmonary vascular tone and RV burden in HFpEF due to high blood pressure (HBP), by using the phosphodiesterase-5 (PDE5) inhibitor sildenafil.

NCT ID: NCT01053091 Completed - Heart Failure Clinical Trials

Effect of Exercise-based Rehabilitation on Circulatory Functions in Patients With Diastolic Heart Failure

Start date: October 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate how exercise-base rehabilitation influences circulatory functions in patients with diastolic heart failure (DHF).

NCT ID: NCT01047631 Completed - Clinical trials for Heart Failure With Preserved Ejection Fraction

Role of Exercise in Diastolic Heart Failure

Start date: December 2008
Phase: N/A
Study type: Interventional

Diastolic heart failure is now being recognized as a key form of heart failure in older people. The focus of this research is to study ways to improve and maintain physical activity and functioning. This knowledge may improve the health and well-being in people with diastolic heart failure.

NCT ID: NCT01046838 Completed - Clinical trials for Heart Failure, Diastolic

SIDAMI - Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (AMI)

SIDAMI
Start date: December 2009
Phase: Phase 4
Study type: Interventional

In patients with Doppler echocardiographic signs of elevated LV filling pressures despite preserved LV systolic function after AMI treatment with the phosphodiesterase inhibitor sildenafil 40 mg three times daily for 9 weeks will compared with placebo 1. Improve resting LV filling and cardiac hemodynamics. 2. Improve exercise capacity. 3. Improve filling pattern and cardiac hemodynamics during exercise.

NCT ID: NCT01030991 Completed - Clinical trials for Heart Failure With Preserved Ejection Fraction

Classification of Heart Failure With Preserved Ejection Fraction

Start date: July 1, 2008
Phase:
Study type: Observational

The purpose of this study is to create a classification system for the heterogenous disorder of heart failure with preserved ejection fraction (HFpEF).

NCT ID: NCT00959660 Completed - Obesity Clinical Trials

Exercise Intolerance in Elderly Patients With Diastolic Heart Failure

SECRET
Start date: February 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effects of weight loss via hypocaloric diet, aerobic exercise training, combined hypocaloric diet and exercise training, and attention control in patients with heart failure and a normal ejection fraction (HFNEF) and body mass index greater than or equal to 30.

NCT ID: NCT00939640 Completed - Clinical trials for Diastolic Heart Failure

Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure

DASH-DHF
Start date: July 2009
Phase: N/A
Study type: Interventional

Heart failure with preserved systolic function (HF-PSF, or 'diastolic heart failure') accounts for half of hospitalizations for heart failure in patients over the age of 65. Most HF-PSF patients have systemic hypertension (HTN), and characteristic HTN-induced cardiovascular changes contribute to HF-PSF. However, it is unclear why most patients with HTN never develop HF-PSF or which specific aspects of HTN predispose to HF-PSF. In the Dahl S rat, the primary animal model of HF-PSF, high dietary sodium intake suppresses the systemic renin-angiotensin-aldosterone system, but upregulates renal and cardiac renin-angiotensin-aldosterone system by inducing oxidative stress. In humans, the magnitude of blood pressure response to sodium ingestion and depletion can categorize subjects as "salt-resistant" and "salt-sensitive." Human salt sensitivity is associated with structural and loading conditions that increase the risk for HF-PSF, including HTN, ventricular hypertrophy and diastolic dysfunction, arterial stiffening, and increased plasma volume. High dietary sodium intake induces oxidative stress in salt-sensitive humans. In humans with HTN and normal ventricular systolic function that do not have heart failure, increased oxidative stress predicts impaired exercise capacity, ventricular hypertrophy, diastolic dysfunction, arterial stiffening, and vascular endothelial dysfunction. The investigators have proposed that "salt sensitivity" and the accompanying oxidative stress on the typical high-sodium Western diet may contribute to the initiation and progression of HF-PSF. In patients with HF-PSF, the investigators will relate dietary changes to biochemical and cardiovascular functional measures. The investigators will study subjects on ad-lib diet and and following three weeks of rigorous dietary modification with the Dietary Approaches to Stop Hypertension (DASH)/sodium-restricted diet (SRD). This diet is richer in natural antioxidants and lower in sodium than the usual American diet. The DASH/SRD is recommended to lower blood pressure in patients with HTN, and is particularly effective in elderly, obese, and salt-sensitive hypertensives. Dietary sodium restriction is recommended for all HF patients including those with HF-PSF. The investigators hypothesize that the DASH/SRD will have favorable effects on oxidative stress, ventricular and vascular function, and blood pressure control in patients with hypertensive HF-PSF.

NCT ID: NCT00846404 Active, not recruiting - Clinical trials for Diastolic Dysfunction

Markers of Oxidative Stress Diastolic Dysfunction

ODDS
Start date: July 2006
Phase: N/A
Study type: Observational

This study is to look at the differences between people who have evidence of abnormal heart relaxation (diastolic dysfunction) on sound wave pictures of the heart (an echocardiogram) compared to those who do not. If you have abnormal relaxation, it can be a cause of shortness of breath or can be present without knowing about it. A condition known as oxidative stress mayb e associated with this abnormal relaxation. This condition occurs when abnormal oxygen injures heart cells. We would like to learn if patients with abnormal relaxation have increased oxidative stress.